RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Neuro, Unless the authorized share limit is increased again (current limit is 105 mil shares), there are only ~38 mil shares available for issuance in a financing (current fully diluted share count is ~67 mil). And that 38 mil share figure has to include any warrants that are part of the deal. This will limit the amount of money that can be raised to approx $5 mil, with a deal looking something like this --

a) 25 mil shares issued at .20 cents (raises $5 mil), plus 13 mil warrants.


Or, if the number of warrants equals the number of shares, then the deal would look something like this -

b) 19 mil shares issued at .20 cents (raises $3.8 mil), plus 19 mil warrants.


So using all the 38 mil available shares, the most we could raise is approx $5 mil, if the deal goes through at .20 cents/share. At .25 cents we could raise approx $6.25 mil, less the usual transaction fees. Of course it remains to be seen if there will be an additional convertible element attached to the deal, toxic (floorless) or otherwise.